Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Protox Therapeutics completes US$2.3 million private placement

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Protox Therapeutics Inc.

On May 20, 2009, Protox Therapeutics Inc. (TSX: PRX) announced that it had closed its previously announced private placement of common shares, resulting in gross proceeds to Protox of approximately $2.31 million. Canaccord Capital Corporation acted as placement agent for the announced $1.5 million private placement and exercised an over-allotment option to sell common shares of Protox for additional gross proceeds of approximately $0.81 million. Protox will use the net proceeds of the offering to finance its clinical activities. Protox is a leader in advancing novel, receptor targeted fusion proteins. Protox was advised on this transaction by Fasken Martineau with a team that included Iain Mant and Benjamin Lee, assisted by paralegal Chin Yen Lee.

Team

    Subscribe

    Receive email updates from our team

    Subscribe